BLLN logo

BillionToOne Inc. (BLLN)

$97.50

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BLLN

Market cap

$4.66B

EPS

0.14

P/E ratio

138.1

Price to sales

11.65

Dividend yield

--

Beta

-0.226827

Price on BLLN

Previous close

$96.31

Today's open

$99.12

Day's range

$94.11 - $100.01

52 week range

$61.96 - $150.44

Profile about BLLN

CEO

--

Employees

713

Headquarters

Menlo Park, CA

Exchange

Nasdaq Global Select

Shares outstanding

47774848

Issue type

Common Stock

BLLN industries and sectors

Healthcare

Medical Diagnostics & Screening

News on BLLN

BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Piper Sandler 38th Annual Healthcare Conference.

news source

GlobeNewsWire • 4 hours ago

news preview

BillionToOne: 3 Key Takeaways for Long-Term Investors

BillionToOne raised 2026 revenue guidance to $460 million to $470 million. Third-quarter revenue reached $123 million, up 47% year over year.

news source

The Motley Fool • Nov 15, 2026

news preview

BillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference Transcript

BillionToOne, Inc. ( BLLN ) 2026 UBS Global Healthcare Conference November 10, 2026 2:00 PM EST Company Participants Oguzhan Atay - Co-Founder, Chairman & CEO Presentation Unknown Analyst Good afternoon. I'm Doug Schenkel with UBS, and it's my pleasure to welcome Oguzhan Atay, Co-Founder and Chief Executive Officer of BillionToOne.

news source

Seeking Alpha • Nov 11, 2026

news preview

Billiontoone Q3 Earnings Call Highlights

Billiontoone NASDAQ: BLLN raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income.

news source

MarketBeat • Nov 5, 2026

news preview

BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript

BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Nov 5, 2026

news preview

BillionToOne (BLLN) Surpasses Q3 Earnings and Revenue Estimates

BillionToOne (BLLN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera. Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.

news source

Seeking Alpha • Oct 29, 2026

news preview

BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth

BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BillionToOne Inc.

Open an M1 investment account to buy and sell BillionToOne Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BLLN on M1